Sitzung

43 - Freie Mitteilung
Colorectal I
16. Mai 2019, 08:30 - 10:00, Szenario 1, 5. OG

Abstract

7
Primary tumour resection in patients with incurable colorectal cancer
C. Gingert1, C. Simillis2, E. Kalakouti2, T. Afxentiou2, D. Cunningham2, M. Adamina1, P. Tekkis2, Presenter: C. Gingert1 (1Winterthur, 2London/UK)

Ziel
At diagnosis, about 1 in 4 patients with colorectal cancer present with synchronous metastases, which are unresectable in 75% of these patients. An important question which remains unanswered for those patients is whether the best treatment strategy is primary tumour resection (PTR) with chemotherapy, or immediate chemotherapy without PTR.
Methoden
A systematic literature review and meta-analysis was performed to compare survival and adverse events in patients with incurable colorectal cancer undergoing PTR versus primary tumour intact (PTI), both including modern chemotherapy regimen. An inverse-variance random-effects model was used for the meta-analysis.
Resultate
75 studies were included, reporting on 129’994 participants (82’951 PTR; 47’043 PTI). PTR increased overall survival (hazard ratio [HR] 0∙58, P<0∙0001) by 7∙5 months (mean difference [MD] 7∙53 months, P<0∙0001) compared to PTI. PTR resulted in longer cancer-specific survival (HR 0∙44, P<0∙0001; MD 10∙01, P<0∙0001) and progression-free survival (HR 0∙75, P<0∙0001; MD 1∙70, P<0∙0001). PTR also improved overall survival during subgroup analysis of: patients receiving chemotherapy (HR 0∙57, P<0∙0001; MD 7∙27, P<0∙0001), patients receiving bevacizumab (HR 0∙56, P=0∙05; MD 10∙56, P=0∙01), elderly patients (HR 0∙46, P<0∙0001; MD 8∙72, P<0∙0001), asymptomatic patients (HR 0∙66, P<0∙0001; MD 3∙86, P=0∙002), studies with propensity analysis (HR 0∙62, P<0∙0001; MD 5∙68, P=0∙0003). PTR had 4∙5% perioperative mortality and 22∙4% morbidity (major adverse events 10∙2%, minor 18∙5%, reoperation 2∙5%, intraabdominal collection/sepsis 2∙2%, anastomotic leak 1∙6%). PTI was associated with 21∙7% morbidity (obstruction 14∙4%, anaemia 11∙0%, haemorrhage 1∙5%, perforation 0.6%, adverse events requiring surgery 15∙8%). Non-resectional surgery resulted in 10∙6% perioperative mortality and 21∙7% morbidity (major 7∙9%, minor 21∙7%, reoperation 0∙1%).
Schlussfolgerung
PTR in patients with incurable colorectal cancer results in an appreciable improvement of survival without a significant increase in overall complications. PTR should be considered by the multidisciplinary team on an individual patient basis.
Für statistische Zwecke und um bestmögliche Funktionalität zu bieten, speichert diese Website Cookies auf Ihrem Gerät. Das Speichern von Cookies kann in den Browser-Einstellungen deaktiviert werden. Wenn Sie die Website weiter nutzen, stimmen Sie der Verwendung von Cookies zu.